Matthew Austin, DO
Internal Medicine · Oklahoma City, OKNPI 1861753287
Payments from drug & device makers
Across 348 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$719
- GSK$694
- AbbVie$587
- Lilly USA, LLC$437
- Abbott$436
- Novo Nordisk$401
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,265100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 51 | $719 |
| GSK | 60 | $694 |
| AbbVie(2 entities) | 40 | $587 |
| Lilly USA, LLC | 29 | $437 |
| Abbott | 31 | $436 |
| Novo Nordisk | 29 | $401 |
| AstraZeneca | 19 | $397 |
| Astellas Pharma US Inc | 11 | $218 |
| Amgen(2 entities) | 11 | $178 |
| Boehringer Ingelheim | 8 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $137 |
| Exact Sciences | 7 | $108 |
| Sumitomo Pharma America, Inc. | 5 | $103 |
| Bayer | 5 | $84 |
| Sanofi Pasteur Inc. | 5 | $76 |
| Madrigal Pharmaceuticals | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $55 |
| Merck | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Hologic Sales And Service, LLC | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 3 | $28 |
| Edwards Lifesciences | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Nevro Corp. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $9 |
How this compares
$5,265 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $152,278 |
| MounjaroTirzepatide | 88 | $107,736 |
| JardianceEmpagliflozin | 81 | $97,363 |
| OzempicSemaglutide | 68 | $80,355 |
| FarxigaDapagliflozin Propanediol | 27 | $39,413 |
| JanuviaSitagliptin Phosphate | 26 | $27,972 |
| EntrestoSacubitril/Valsartan | 16 | $23,611 |
| TrulicityDulaglutide | 11 | $23,100 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $22,537 |
| XareltoRivaroxaban | 15 | $21,233 |
| Atorvastatin Calcium | 688 | $13,788 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,649 |
| GemtesaVibegron | 12 | $10,140 |
| BelsomraSuvorexant | 12 | $9,785 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $719 | $152,278130 claims |
| Lilly USA, LLCMounjaro, Trulicity | $437 | $130,83699 claims |
| Boehringer IngelheimJardiance | $152 | $97,36381 claims |
| Novo NordiskOzempic | $401 | $80,35568 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $397 | $58,01461 claims |
| MerckJanuvia, Belsomra | $50 | $37,75738 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $694 | $31,32143 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $103 | $10,14012 claims |
| AbbVieSynthroid | $587 | $5,13756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Samid FarooquiOklahoma City$129K
- Minh PhanOklahoma City$77K
- Ali JafryOklahoma City$33K
- Stuart SchraderOklahoma City$29K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.